Gene · 2823
Papers1,924
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
241 to 260 of 1,924
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Rhein exerts anti-multidrug resistance in acute myeloid leukemia via targeting FTO to inhibit AKT/mTOR. | Anticancer Drugs | 2024 | 38728095 | PubTator, text mining | PubMed |
| Synchronous profiling of mRNA N6-methyladenosine modifications and mRNA expression in high-grade serous ovarian cancer: a pilot study. | Sci Rep | 2024 | 38714753 | PubTator, text mining | PubMed |
| Small molecule inhibitors targeting m6A regulators. | J Hematol Oncol | 2024 | 38711100 | PubTator, text mining | PubMed |
| FTO elicits tumor neovascularization in cancer-associated fibroblasts through eliminating m6A modifications of multiple pro-angiogenic factors. | Cancer Lett | 2024 | 38685450 | PubTator, text mining | PubMed |
| Correction: m6A-Induced lncRNA MEG3 Promotes Cerebral Ischemia-Reperfusion Injury Via Modulating Oxidative Stress and Mitochondrial Dysfunction by hnRNPA1/Sirt2 Axis. | Mol Neurobiol | 2024 | 38652353 | PubTator, text mining | PubMed |
| Development of m6A/m5C/m1A regulated lncRNA signature for prognostic prediction, personalized immune intervention and drug selection in LUAD. | J Cell Mol Med | 2024 | 38647237 | PubTator, text mining | PubMed |
| ALKBH5 modulates macrophages polarization in tumor microenvironment of ovarian cancer. | J Ovarian Res | 2024 | 38637813 | PubTator, text mining | PubMed |
| Comprehensive analysis of m6A modification in immune infiltration, metabolism and drug resistance in hepatocellular carcinoma. | Cancer Cell Int | 2024 | 38627760 | PubTator, text mining | PubMed |
| RNA M6A modification shaping cutaneous melanoma tumor microenvironment and predicting immunotherapy response. | Pigment Cell Melanoma Res | 2024 | 38624045 | PubTator, text mining | PubMed |
| Ginsenoside Rg1 Alleviates Sepsis-Induced Acute Lung Injury by Reducing FBXO3 Stability in an m6A-Dependent Manner to Activate PGC-1α/Nrf2 Signaling Pathway. | AAPS J | 2024 | 38622374 | PubTator, text mining | PubMed |
| Understanding YTHDF2-mediated mRNA degradation by m6A-BERT-Deg. | Brief Bioinform | 2024 | 38622358 | PubTator, text mining | PubMed |
| N6-Methyladenosine-Modified KREMEN2 Promotes Tumorigenesis and Malignant Progression of High-Grade Serous Ovarian Cancer. | Lab Invest | 2024 | 38615731 | PubTator, text mining | PubMed |
| Targeting FTO induces colorectal cancer ferroptotic cell death by decreasing SLC7A11/GPX4 expression. | J Exp Clin Cancer Res | 2024 | 38600610 | PubTator, text mining | PubMed |
| HSPA4 upregulation induces immune evasion via ALKBH5/CD58 axis in gastric cancer. | J Exp Clin Cancer Res | 2024 | 38589927 | PubTator, text mining | PubMed |
| Long non-coding RNA GATA6-AS1 is mediated by N6-methyladenosine methylation and inhibits the proliferation and metastasis of gastric cancer. | World J Gastrointest Oncol | 2024 | 38577476 | PubTator, text mining | PubMed |
| A covalent compound selectively inhibits RNA demethylase ALKBH5 rather than FTO. | RSC Chem Biol | 2024 | 38576724 | PubTator, text mining | PubMed |
| m6A-dependent upregulation of DDX21 by super-enhancer-driven IGF2BP2 and IGF2BP3 facilitates progression of acute myeloid leukaemia. | Clin Transl Med | 2024 | 38572589 | PubTator, text mining | PubMed |
| A LATS2 and ALKBH5 positive feedback loop supports their oncogenic roles. | Cell Rep | 2024 | 38568805 | PubTator, text mining | PubMed |
| Correction: The epigenetic downregulation of LncGHRLOS mediated by RNA m6A methylase ZCCHC4 promotes colorectal cancer tumorigenesis. | J Exp Clin Cancer Res | 2024 | 38561777 | PubTator, text mining | PubMed |
| Correction to: BMP2 Modified by the m6A Demethylation Enzyme ALKBH5 in the Ossification of the Ligamentum Flavum Through the AKT Signaling Pathway. | Calcif Tissue Int | 2024 | 38557868 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2823/papers?page=13